Biorestorative Therapies Share Price (NASDAQ: BRTX)

$1.55

▲

0.03

(1.97%)

Live

Last updated on August 19, 2025 at 12:21 AM IST

$₹

Check the interactive Biorestorative Therapies Stock chart to analyse performance

Biorestorative Therapies Inc Key Stats

Check Biorestorative Therapies key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$1.52
Open	$1.51
Market Capitalization	$11.4M
Today's Volume	$25.8K
Revenue TTM	$391.0K
EBITDA	$-12.1M
Earnings Per Share (EPS)	$-1.26
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-117.16%

Stock Returns calculator for Biorestorative Therapies Stock including INR - Dollar returns

The Biorestorative Therapies stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Biorestorative Therapies investment value today

Current value as on today

₹95,789

Returns

₹4,211

(-4.21%)

Returns from Biorestorative Therapies Stock

₹8,284 (-8.28%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Biorestorative Therapies Stock

-50%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Biorestorative Therapies Stock from India on INDmoney has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Biorestorative Therapies Inc

Name
Holdings %
Name
Holdings %
Geode Capital Management, LLC
0.80%
StoneX Group Inc
0.68%
Wealth Alliance, LLC
0.53%
Morgan Stanley - Brokerage Accounts
0.51%
Vanguard Group Inc
0.40%
State Street Corp
0.27%

Analyst Recommendation on Biorestorative Therapies Stock

Rating

Trend

Buy

87%Buy

12%Hold

0%Sell

Based on 8 Wall street analysts offering stock ratings for Biorestorative Therapies(by analysts ranked 0 to 5 stars)

Biorestorative Therapies Share Price Target

What analysts predicted

Upside of 738.71%

Target:

$13.00

Current:

$1.55

Biorestorative Therapies share price target is $13.00, a slight Upside of 738.71% compared to current price of $1.55 as per analysts' prediction.

Biorestorative Therapies Stock Insights

Price Movement
In the last 7 days, BRTX stock has moved up by 7.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 25.0K → 303.3K (in $), with an average increase of 91.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -5.33M → -2.65M (in $), with an average increase of 101.0% per quarter
BRTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 67.4% return, outperforming this stock by 71.8%
BRTX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 100.9% return, outperforming this stock by 153.4%
Price to Sales
ForBRTX every $1 of sales, investors are willing to pay $31.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.6 for every $1 of sales.

Biorestorative Therapies Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$130.0K	↑ 17.12%
Net Income	$-14.6M	↑ 17.02%
Net Profit Margin	-11.3K%	↑ 9.69%

	FY20	Y/Y Change
Revenue	$77.0K	↓ 40.77%
Net Income	$-11.3M	↓ 23.04%
Net Profit Margin	-14.6K%	↓ 3372.24%

	FY21	Y/Y Change
Revenue	$46.0K	↓ 40.26%
Net Income	$-44.3M	↑ 293.01%
Net Profit Margin	-96.3K%	↓ 81671.66%

	FY22	Y/Y Change
Revenue	$119.8K	↑ 160.43%
Net Income	$-13.2M	↓ 70.16%
Net Profit Margin	-11.0K%	↑ 85274.54%

	FY23	Y/Y Change
Revenue	$145.8K	↑ 21.7%
Net Income	$-10.4M	↓ 21.21%
Net Profit Margin	-7.1K%	↑ 3891.77%

	FY24	Y/Y Change
Revenue	$401.0K	↑ 175.03%
Net Income	$-9.0M	↓ 13.81%
Net Profit Margin	-2.2K%	↑ 4905.95%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$35.0K	↑ 81.35%
Net Income	$-2.2M	↓ 21.31%
Net Profit Margin	-6.4K%	↑ 8286.28%

	Q2 FY24	Q/Q Change
Revenue	$89.1K	↑ 154.57%
Net Income	$-4.0M	↑ 81.2%
Net Profit Margin	-4.5K%	↑ 1830.77%

	Q3 FY24	Q/Q Change
Revenue	$233.6K	↑ 162.18%
Net Income	$-1.1M	↓ 72.91%
Net Profit Margin	-467.22%	↑ 4054.17%

	Q4 FY24	Q/Q Change
Revenue	$43.3K	↓ 81.46%
Net Income	$-1.6M	↑ 49.91%
Net Profit Margin	-3.8K%	↓ 3311.41%

	Q1 FY25	Q/Q Change
Revenue	$25.0K	↓ 42.26%
Net Income	$-5.3M	↑ 226.36%
Net Profit Margin	-21.4K%	↓ 17580.57%

	Q2 FY25	Q/Q Change
Revenue	$303.3K	↑ 1113.2%
Net Income	$-2.7M	↓ 50.26%
Net Profit Margin	-875.79%	↑ 20483.41%

FY20

FY21

FY22

FY23

FY24

	FY20	Y/Y Change
Profit	$77.0K	-

	FY21	Y/Y Change
Profit	$46.0K	↓ 40.26%

	FY22	Y/Y Change
Profit	$119.8K	↑ 160.43%

	FY23	Y/Y Change
Profit	$-19.9K	↓ 116.64%

	FY24	Y/Y Change
Profit	$372.9K	↓ 1970.72%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-7.7K	-

	Q2 FY24	Q/Q Change
Profit	$82.6K	↓ 1171.05%

	Q3 FY24	Q/Q Change
Profit	$215.4K	↑ 160.69%

	Q4 FY24	Q/Q Change
Profit	$40.0K	↓ 81.44%

	Q1 FY25	Q/Q Change
Profit	$22.1K	↓ 44.72%

	Q2 FY25	Q/Q Change
Profit	$294.6K	↑ 1233.44%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-6.9M	↑ 35.54%
Investing Cash Flow	$-35.6K	↑ 176.87%
Financing Cash Flow	$6.8M	↑ 42.97%

	FY20	Y/Y Change
Operating Cash Flow	$-2.0M	↓ 71.61%
Investing Cash Flow	$-35.6K	↑ 0.0%
Financing Cash Flow	$5.0M	↓ 26.49%

	FY21	Y/Y Change
Operating Cash Flow	$-3.3M	↑ 69.52%
Investing Cash Flow	$-30.7K	↓ 13.96%
Financing Cash Flow	$21.3M	↑ 324.15%

	FY22	Y/Y Change
Operating Cash Flow	$-5.9M	↑ 76.3%
Investing Cash Flow	$-13.5M	↑ 43866.95%
Financing Cash Flow	$21.1M	↓ 1.17%

	FY23	Y/Y Change
Operating Cash Flow	$-6.4M	↑ 9.53%
Investing Cash Flow	$3.3M	↓ 124.13%
Financing Cash Flow	$2.3M	↓ 88.85%

	FY24	Y/Y Change
Operating Cash Flow	$-8.2M	↑ 27.99%
Investing Cash Flow	$514.5K	↓ 84.18%
Financing Cash Flow	$7.4M	↑ 214.18%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-2.3M	↑ 30.7%
Investing Cash Flow	$-4.9M	-
Financing Cash Flow	$7.5M	↑ 8678.87%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-1.9M	↓ 19.53%
Investing Cash Flow	$3.0M	↓ 160.33%
Financing Cash Flow	$-12.8K	↓ 100.17%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-1.7M	↓ 8.88%
Investing Cash Flow	$936.8K	↓ 68.49%
Financing Cash Flow	$0.0	↓ 100.0%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-2.3M	↑ 38.14%
Investing Cash Flow	$1.5M	↑ 63.61%
Financing Cash Flow	$-126.3K	-

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-2.8M	↑ 18.35%
Investing Cash Flow	$2.4M	↑ 54.44%
Financing Cash Flow	$1.1M	↓ 965.07%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-2.7M	↓ 3.06%
Investing Cash Flow	$2.1M	↓ 9.92%
Financing Cash Flow	$888.1K	↓ 18.72%

Biorestorative Therapies Technicals Summary

Sell

Neutral

Buy

Biorestorative Therapies is currently in a neutral trading position according to technical analysis indicators.

Biorestorative Therapies Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biorestorative Therapies Inc	-4.4%	-23.81%	-9.79%	-52.5%	-78.35%
Regeneron Pharmaceuticals, Inc.	6.39%	-14.65%	-51.51%	-6.14%	-7.82%
Beone Medicines Ltd	10.08%	34.96%	66.94%	83.8%	36.85%
Vertex Pharmaceuticals Incorporated	-14.33%	-15.0%	-19.52%	31.35%	45.44%
Alnylam Pharmaceuticals, Inc.	40.06%	79.56%	63.55%	107.86%	227.15%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biorestorative Therapies Inc	NA	NA	0.0	-1.55	-1.17	-0.54	NA	0.82
Regeneron Pharmaceuticals, Inc.	14.62	14.62	1.19	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.94	27.94	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biorestorative Therapies Inc	Buy	$11.4M	-78.35%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.5B	-7.82%	14.62	31.37%
Beone Medicines Ltd	NA	$38.8B	36.85%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.7B	45.44%	27.94	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.0B	227.15%	NA	-12.96%

About Biorestorative Therapies Inc

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

Organization	Biorestorative Therapies
Employees	11
CEO	Mr. Lance Alstodt
Industry	Biotechnology

Key Management of Biorestorative Therapies Inc

Name	Title
Mr. Lance Alstodt	Chairman of the Board, President & CEO
Mr. Robert Eugene Kristal	Chief Financial Officer
Mr. Francisco J. Silva	VP of Research & Development, Secretary and Director
Stephen Kilmer	Investor Relations Officer

Important FAQs about investing in BRTX Stock from India :

What is Biorestorative Therapies share price today?

Biorestorative Therapies share price today is $1.55 as on August 19, 2025 at 12:21 AM IST. Biorestorative Therapies share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Biorestorative Therapies share?

Biorestorative Therapies share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Biorestorative Therapies stock price today, August 19, 2025 at 12:21 AM IST is trending at $1.55, lower by 39.22% versus the 52 week high.

How to invest in Biorestorative Therapies Stock (BRTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Biorestorative Therapies on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Biorestorative Therapies Shares that will get you 0.9677 shares as per Biorestorative Therapies share price of $1.55 per share as on August 19, 2025 at 12:21 AM IST.

What is the minimum amount required to buy Biorestorative Therapies Stock (BRTX) from India?

Indian investors can start investing in Biorestorative Therapies (BRTX) shares with as little as ₹87.3775 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Biorestorative Therapies stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Biorestorative Therapies share’s latest price of $1.55 as on August 19, 2025 at 12:21 AM IST, you will get 6.4516 shares of Biorestorative Therapies. Learn more about fractional shares .

What are the returns that Biorestorative Therapies has given to Indian investors in the last 5 years?

Biorestorative Therapies stock has given -78.35% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?